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Previewsknockdown. Notably, 9 of these factors
affected erythroid development whereas
8 factors affected myeloid development.
More than half of these factors were pre-
dicted to regulate the specific lineage
based on the sequence or expression-
based model. Moreover, two of these
factors, HIF3A and AFF1 (encoding the
AF9 protein), were not previously impli-
cated in erythropoiesis but emerged
from this study based on their expression
profile. The scope of the analysis per-
formed in this study on human hemato-
poietic progenitors provides a rich
resource for identifying regulatory124 Cell Stem Cell 8, February 4, 2011 ª2011networks controlling HSC self-renewal,
differentiation, and lineage determination.REFERENCES
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Combining embryological insight with careful analysis of early stage cardiomyocyte differentiation, Kattman
et al. (2011) in this issue of Cell Stem Cell have defined minimal culture conditions to efficiently produce
cardiomyocytes from hESCs and hiPSCs. The lessons learned are applicable to the derivation of other
organotypic cell types.The promise of stem cell biology as an
inexhaustible source of differentiated cells
for research applications and disease
therapies is predicated on the ability to
efficiently produce organotypic cells.
A complementary body of knowledge
from over a century of experimental
embryology offers many insights into
fundamental mechanisms of differentia-
tion. The two fields have come together
nicely in a paper by Kattman et al. in this
issue, describing the efficient and
controlled differentiation of pluripotent
stem cells (PSCs) into cardiomyocytes
(Kattman et al., 2011). The trick to working
out the protocol was combining the use
of embryological markers with careful
titrations of signals that drive cells along
discrete steps toward terminally differenti-
ated, functional cardiomyocytes. The
novelty resides not in the particular
molecules that were used to drive the
production of cardiomyocytes but, rather,
in theapproach they took toestablish idealconcentrations and exposure windows.
Although embryological development
turned out to be a good guide, significant
differences between PSC lines, even
from the same species, necessitated
devising a systematic approach that relied
on parsing development into discrete
steps and optimizing the use of a small
number of embryological signals in each.
These findings epitomize the extrapola-
tion of experimental embryology to stem
cell biology and reinforce the idea that
embryonicdevelopment holdsmanyclues
for controlled differentiation of stem cells.
The strategy takenbyKattman et al. was
enabled by their characterization of the
VEGF receptor-2 (called Flk-1 or KDR)
and PDGF receptor-a (PDGFRa) together
as enriching cardiogenic mesoderm,
which can form cardiomyocytes, endothe-
lial cells, and smooth muscle, as distinct
from hematopoietic progenitors in the
KDR+, PDGFRa population. Since the
divergent TGFb molecules Nodal andBMP, along with Wnt, induce cardiac
mesoderm in embryos (Mercola et al.,
2010), Kattman et al. optimized the
concentration and duration of Activin (as
a surrogate of Nodal) and BMP treatment
(Figure 1). Strikingly, small differences
in concentrations affect the yield of KDR+,
PDGFRa+ cells dramatically and, conse-
quently, reduce the yield of cardiomy-
coytes. Although anticipated by embryolo-
gists knowledgeable of threshold effects
that subtlegradations inActivin concentra-
tion have on inducing different types of
mesoderm, originally shown in Xenopus
(Green et al., 1992) and later generalized
to the mouse and zebrafish (Freeman and
Gurdon, 2002), the finding is puzzling
from a signal transduction perspective
because it is not clear howa small concen-
tration difference is reflected in qualita-
tively different genomic and develop-
mental responses. Timing was as crucial
as dose, because greatly reduced Activin
and Wnt signaling were subsequently
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Figure 1. Directing Cardiomyocyte Differentiation
A small number of factors can efficiently drive cardiomyogenesis in PSCs (upper panel) in an apparent
recapitulation of the processes that direct heart development, as depicted for mouse between days
3–8 of gestation (E3-8; lower panel). Nodal, Wnt, and BMP induce cardiogenic mesoderm (blue), but
then need to be blocked in order for cardiac development to proceed, constraining heart development
to a region of anterior endoderm in the late gastrula-stage embryo (red region of the E7-7.5 embryo, lower
panel). As a result of this work, the emphasis of future research will shift to decipher how diverse types of
mature cardiomyocytes can be generated, and other lineages can be similarly derived, such as hepato-
cytes from endoderm (brown) and hematopoetic cells from posteriorized mesoderm (purple).
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Previewsrequired for commitment to the cardiac
lineageanddifferentiation, evident by tran-
scripts for NKX2.5, TBX5, ISL1, and
MEF2C encoding cardiac transcription
factors. This pattern also reflects embry-
ology because, after transiently inducing
and patterning primitive streak mesendo-
derm, Nodal, BMP, and Wnt signaling
must be inhibited by secreted antagonists
from the anterior visceral endoderm
(AVE), including Dickkopf-1 (Dkk1), to
induce heart tissue, effectively constrain-
ing cardiogenesis to a small region of ante-
rior mesoderm classically called the heart
field (Figure 1) (Mercola et al., 2010).Attempting to decipher and recapitu-
late development in a dish of PSCs has
its limits. First, cell-surface markers often
lack specificity for the desired tissue, or
their patterns of expression cannot parse
a developmental program as finely as
desired. Second, intrinsic differences
between PSC cell lines make them
respond differently to developmental
signals. The first imposes a technical limit
on the ability to isolate progenitors at each
developmental stage and, hence, the
ability to unravel the signals that drive
them to the next. Moreover, earlier stage
cells are less capable than later stageCell Stem Cell 8progenitors or precursors of producing
pure populations of organotypic deriva-
tives. This problem is beautifully illus-
trated by the Kattman et al. finding that
FACS-isolated KDR+, PDGFRa+ cells do
not generate a higher percentage of cardi-
omyocytes than does the unsorted parent
population (see Figure 2B of Kattman
et al., 2011). This failure could simply
reflect that early stage cells are poised
to generate geometrically more cell types.
For instance, Nkx2.5+, Isl1+ cardiac
precursors more efficiently yield myocar-
dial cells than do the early KDR+,
PDGFRa+ cardiogenic mesoderm (Do-
mian et al., 2009). Alternatively, it could
alsomean that themarker-based isolation
of progenitors eliminates cells that
secrete inducing signals or does not
capture all the cardiomyogenic progeni-
tors. The latter possibility is consistent
with multiple potential lineages giving
rise to cardiomyocytes. For instance, it is
unclear whether all cardiomyocytes in
the embryo arise from KDR+ progenitors
or whether a KDR source also exists
in embryos and ESC cultures (Blin
et al., 2010). Moreover, the recognition
that different PSC lines require individu-
ally tailored differentiation protocols
demonstrates how much remains to be
learned about line-to-line differences, in
particular, vestiges of diverse origins and
methods of reprogramming in induced
pluripotent stem cells (Stadtfeld and
Hochedlinger, 2010). The clinical implica-
tion of this finding for hiPSC-based
therapy means that protocols must be
customized for each patient.
The efficient production of cardiomyo-
cytes has many applications, including
use in regenerative medicine and drug
safety evaluation (Segers and Lee,
2008). However, this and other protocols
generate electrically and mechanically
immature cells that resemble fetal, rather
than adult, cardiomyocytes. Immature
cardiomyocytes do not generate the
contractile force of mature myocytes,
and their ion channel properties diminish
the predictive value of in vitro analyses,
such as for cardiotoxicity, and present
potential risk in transplantation. More-
over, myocytes in the heart are naturally
diverse, with highly specialized physio-
logical attributes (e.g., pacing, conduct-
ing and working myocytes) and regional
heterogeneity—even within the ventric-
ular wall—that are critical for normal, February 4, 2011 ª2011 Elsevier Inc. 125
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Previewsfunction and heart pathologies. Thus,
there is an obvious need to understand
the signals and cues that direct cardio-
myocyte diversity and promote electrical
and mechanical maturation. This goal is
challenging using embryos generated
with conventional transgenic technolo-
gies since many genes have multiple
essential roles and their inactivation early
on can mask later functions. As a result,
PSCs represent a straightforward means
to dissect the molecular basis for late-
stage developmental or maturational
events by bringing in novel technologies
such as siRNAs, miRNAs, or small mole-
cules, especially using high-throughput
technology.
In summary, embryology redux can
lead to efficient, directed differentiation
of PSCs, enhancing knowledge of
embryogenesis and increasing the rele-126 Cell Stem Cell 8, February 4, 2011 ª2011vance of PSC-derived cells for practical
applications and research. This and other
recent examples of efficient differentiation
[e.g., pancreatic endocrine cells and
motor neurons (Kroon et al., 2008; Wich-
terle et al., 2002) bring us one step closer
to being able to scrutinize highly complex
normal and pathological behaviors of
terminally differentiated cells in culture
dishes.REFERENCES
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Individuals carrying deleterious BRCA1 mutations typically develop basal-like rather than luminal breast
cancers. In this issue of Cell Stem Cell, Proia et al. (2011) study breast tissue from women with heterozygous
BRCA1 mutations and identify molecular mechanisms that regulate mammary progenitor cell differentiation
and bias toward subsequent basal-like tumor formation.Since the early 1990s, investigators have
known that certain families contain
women who exhibit a significant
increased lifetime risk for breast and
ovarian cancer. In this population, the
genetic locus responsible for this risk,
BRCA1, is heterozygous for deleterious
mutations where one copy of the gene is
truncated, mutated, deleted, or silenced
by DNA hypermethylation (Ostermeyer
et al., 1994). Breast tumors that form in
these women are unusual on several
levels. First, the tumors develop at an early
age and are a manifestation of an
increased lifetime risk of developing
breast cancer. Although several BRCA1
functions may be altered in individuals
who bear a mutated copy of the gene,the actual molecular basis for this
increased risk is unknown. Second, the
tissue types that exhibit an increased like-
lihood of developing tumors are restricted
to a small number, mostly breast and
ovarian tissues. Why the increased risk
for cancer does not extend to other
organs or lineages is also amystery. Third,
and the topic of this Preview, the type of
breast cancer that is most typically diag-
nosed in BRCA1 mutation carriers is of
a particular subtype, the highly lethal
basal-like subtype. Understanding how
the BRCA1 protein participates in any of
these threemalignant patterns (Venkitara-
man, 2002) would be amajor step forward
in the effort to treat and eventually eradi-
cate the disease. In this issue of CellStemCell, Proia and colleagues in the Ku-
perwasser laboratorymake use of primary
breast tissue samples isolated from
disease-free BRCA1 mutation carriers
(Proia et al., 2011). The authors present
a carefully crafted study that addresses
the origin of the basal-like phenotype
that predominates in the tumors that
develop in these women. This study
constitutes a cornerstone in the field as
the use of tissues obtained from women
that carry these mutations provides
unparalleled opportunities to gain insights
into the molecular events that underlie the
puzzles noted above. Through a compel-
ling set of supporting data, the authors
reveal that the propensity to generate
basal-like tumors in breast tissue that
